Safety and Pharmacokinetics of a Human IgM anti-Lipid A Monoclonal Antibody in Primary Immune Deficient Patients
— · The Internet Journal of Asthma Allergy and Immunology · 1999
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
The Internet Journal of Asthma Allergy and Immunology · OpenAlex · article · 1999
Abstract
A phase I clinical study of a human IgM anti-lipid A monoclonal antibody was conducted in 24 patients with a primary immunodeficiency syndrome. Six patients each were evaluated at one of four dosage levels: 50 mg, 75 mg, 100 mg or 150 mg. Subjects were observed for both acute adverse events as well as various laboratory parameters over 28 days. In addition, a pharmacokinetic study was done on the single antibody infusion at each dosage level assessing half-life, peak concentration and 24 hr concentration. The results indicated that the infusion may be safely given at all four dosage levels and that the pharmacokinetics of this antibody is probably linear.
Open the resolved locator · 10.5580/de7
Metadata licence: OpenAlex metadata (CC0)